問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳友木
下載
2025-10-01 - 2032-01-31
Condition/Disease
Subjects with locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed after third-generation EGFR TKI treatment
Test Drug
Telisotuzumab Adizutecan (ABBV-400)
Participate Sites8Sites
Recruiting8Sites
2022-05-01 - 2026-03-31
Participate Sites6Sites
Recruiting6Sites
2026-03-16 - 2029-01-31
Participate Sites12Sites
Not yet recruiting2Sites
Recruiting10Sites
2020-11-01 - 2027-06-30
2024-11-01 - 2031-06-30
2023-09-01 - 2029-12-31
Participate Sites13Sites
Recruiting13Sites
2025-03-01 - 2028-03-31
Participate Sites9Sites
Recruiting9Sites
2023-08-31 - 2032-02-12
Not yet recruiting4Sites
Recruiting2Sites
2023-01-01 - 2029-05-19
Participate Sites7Sites
Recruiting7Sites
2023-12-01 - 2031-05-31
Participate Sites11Sites
Recruiting11Sites
全部
